CymitQuimica logo
Apoptose

Apoptose

Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.

Subcategorias de "Apoptose"

Exibir 6 mais subcategorias

Foram encontrados 5599 produtos de "Apoptose"

Ordenar por

Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
produtos por página.
  • Antiproliferative agent-4


    <p>Antiproliferative agent-4 suppresses cancer cell growth with low toxicity, inhibits tumors in mice, and induces apoptosis in EC109 cells.</p>
    Fórmula:C29H35ClO8
    Cor e Forma:Solid
    Peso molecular:547.04
  • Rezatapopt

    CAS:
    <p>Rezatapopt (PC14586) is a p53 reactivator with antitumor activity for the study of locally advanced or metastatic solid tumors.</p>
    Fórmula:C28H31F4N5O2
    Pureza:98.12%
    Cor e Forma:Solid
    Peso molecular:545.57
  • HR-19011

    CAS:
    <p>HR-19011 (Compound 40) is an inducer of eIF2α phosphorylation that increases expression levels of downstream proteins ATF and CHOP,antiproliferative.</p>
    Fórmula:C25H19F6N3O3
    Pureza:99.89%
    Cor e Forma:Solid
    Peso molecular:523.43
  • Topoisomerase I/II inhibitor 8

    CAS:
    <p>TopoisomeraseI/II inhibitor 8 (Compound Ru7) is a dual catalytic inhibitor of TopoisomeraseI/II that induces DNA damage and activates PARP-1, leading to the activation of RIPK1, RIPK3, and MLKL, ultimately causing necroptosis. It shows significant anticancer activity by effectively targeting cancer cell nuclei and inducing cell death through necroptosis, offering substantial clinical potential in overcoming resistance in cancer treatment.</p>
    Fórmula:C14H11Br2NO5S2
    Cor e Forma:Solid
    Peso molecular:497.179
  • SL-176

    CAS:
    <p>SL-176, a WIP1 inhibitor, when combined with GSK-J4, can induce cell cycle arrest and apoptosis (apoptosis), thereby inhibiting tumor growth both in vitro and in vivo.</p>
    Fórmula:C24H48O4Si2
    Cor e Forma:Solid
    Peso molecular:456.806
  • L-threo-Sphingosine C-18

    CAS:
    <p>L-threo-Sphingosine C-18 is a protein kinase C inhibitor.</p>
    Fórmula:C18H37NO2
    Pureza:98%
    Cor e Forma:Solid
    Peso molecular:299.49
  • RIPK1-IN-14

    CAS:
    <p>RIPK1-IN-14 inhibits RIPK1 with 92 nM IC50 and reduces necrotic apoptosis in U937 cells.</p>
    Cor e Forma:Soild
  • FTO-IN-13

    CAS:
    <p>FTO-IN-13 (compound 8t) is a potent FTO inhibitor with antiproliferative properties. It induces apoptosis (cell apoptosis) and reduces the expression of Bcl-2 and Caspase 3 active proteins. Additionally, FTO-IN-13 lowers the expression of MYC and CEBPA genes and demonstrates anticancer activity.</p>
    Fórmula:C18H12Br2N2O4
    Cor e Forma:Solid
    Peso molecular:480.107
  • TRPM7-IN-1

    CAS:
    <p>TRPM7-IN-1 (compound SUD) is a benzamide-urea derivative and an effective inhibitor of TRPM7. This compound induces cell cycle arrest and apoptosis in MCF-7 and BGC-823 cells, reducing their migration capabilities. It decreases vimentin expression while increasing E-cadherin expression. TRPM7-IN-1 reduces TRPM7-like currents and inhibits TRPM7 expression by activating the PI3K/Akt signaling pathway. This compound shows potential as a therapeutic agent for reducing breast and gastric cancer metastasis by targeting TRPM7 expression and activity.</p>
    Fórmula:C23H25N5O3
    Cor e Forma:Solid
    Peso molecular:419.48
  • PIM-1/HDAC-IN-1


    <p>PIM-1/HDAC-IN-1 (4d): inhibits PIM-1 (IC50: 343.87nM), HDAC1 (63.65nM), HDAC6 (62.39nM); induces apoptosis in MCF-7 cells.</p>
    Fórmula:C22H19N3O3
    Cor e Forma:Solid
    Peso molecular:373.4
  • MLS-0053105

    CAS:
    <p>MLS-0053105, a chloromaleimide, functions as a selective inhibitor of BFL-1, exhibiting an IC50 of 0.4 µM against Bfl-1/F-Bid. Its inhibitory potency is over tenfold lower for Bcl-W, Bcl-2, and Bcl-XL, and it shows no activity against Bcl-B and Mcl-1.</p>
    Fórmula:C15H14Cl3N3O2
    Cor e Forma:Solid
    Peso molecular:374.65
  • ERK1/2 inhibitor 11


    <p>ERK1/2 inhibitor 11 (compound L6) is a dual inhibitor of ERK1/2 that promotes the accumulation of DSBs and the degradation of ERK1/2 expression. This compound decreases BCL-2 levels and induces DNA damage by inhibiting PARP and ERK1/2. Additionally, ERK1/2 inhibitor 11 activates caspase 3 to induce apoptosis.</p>
    Fórmula:C15H19N5O2S
    Cor e Forma:Solid
    Peso molecular:333.41
  • Antiangiogenic agent 7

    CAS:
    <p>Antiangiogenic agent 7 (Compound 1) induces apoptosis, elevates Reactive Oxygen Species (Reactive Oxygen Species), and inhibits the intracellular enzyme thioredoxin reductase. It exhibits anticancer activity with IC50 values ranging from 0.08 to 3.5 μM against cervical cancer cells (HeLa), prostate cancer cells (PC-3), and non-small cell lung cancer cells (A549). Additionally, Antiangiogenic agent 7 suppresses tumor growth in a mouse xenograft model.</p>
    Fórmula:C24H26AuN3P2S
    Cor e Forma:Solid
    Peso molecular:647.46
  • CRI9


    <p>CRI9 effectively inhibits the c-MET/PI3K/Akt/mTOR axis, suppressing the proliferation of hepatocellular carcinoma (HCC) cells. This compound exhibits potent cytotoxicity against HCC cells and induces apoptosis.</p>
    Fórmula:C26H18N6O4
    Cor e Forma:Solid
    Peso molecular:478.46
  • 3′-Hydroxyflavanone

    CAS:
    <p>3′-Hydroxyflavanone is a cyclized flavonoid with anti-tumor properties that induces apoptosis in HeLa cells.</p>
    Fórmula:C15H12O3
    Cor e Forma:Solid
    Peso molecular:240.25
  • EGFR-IN-134


    <p>EGFR-IN-134 (compound 3f) is a triazolo[3,4-a]quinoline derivative and functions as a potent EGFR inhibitor with an IC50 of 0.023 µM. It induces apoptosis and necrosis in cells, and causes cell cycle arrest in the G2/M and pre-G1 phases. EGFR-IN-134 modulates the expression of apoptosis-regulating proteins by downregulating anti-apoptotic protein Bcl2 and upregulating pro-apoptotic proteins p53, Bax, and caspases 3, 8, and 9, demonstrating significant antiproliferative and anticancer activities.</p>
    Fórmula:C36H30N6O5
    Cor e Forma:Solid
    Peso molecular:626.66
  • TOPOI/PARP-1-IN-1

    CAS:
    <p>Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].</p>
    Fórmula:C36H38Br2N4O2
    Cor e Forma:Solid
    Peso molecular:718.52
  • Nur77 agonist-1

    CAS:
    <p>Nur77 agonist-1 (Compound 8f) is an orally active Nur77 agonist. It induces ferroptosis by upregulating Nur77 protein expression, increasing reactive oxygen species (ROS) and lipid peroxidation levels, while decreasing GPX4 protein expression. Nur77 agonist-1 binds with affinity to the ligand binding domain of Nur77, with a KD of 13.80 μM. It demonstrates significant antiproliferative activity against various breast cancer cells (IC50: 2.15-3.26 μM) and exhibits low cytotoxicity towards normal cells. This compound is useful for breast cancer research.</p>
    Fórmula:C24H18ClN5O2
    Cor e Forma:Solid
    Peso molecular:443.885
  • SIJ1777

    CAS:
    <p>SIJ1777, a derivative of GNF-7, exhibits potent anticancer effects against melanoma cells harboring BRAFI/II/III mutations. The compound significantly inhibits the activation of MEK, ERK, and AKT. Furthermore, SIJ1777 notably induces apoptosis (cell death) and effectively prevents migration, invasion, and anchorage-independent growth of melanoma cells with BRAFI/II/III mutations.</p>
    Fórmula:C26H23F3N8O2
    Cor e Forma:Solid
    Peso molecular:536.51
  • MLKL-IN-6


    <p>MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.</p>
    Fórmula:C20H18N4O5
    Pureza:98%
    Cor e Forma:Solid
    Peso molecular:394.38